4; is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.
For further information regarding Sucanon®, please visit the Fero Industries, Inc., website at www.feroindustries.com, email us at email@example.com, or call toll-free (855) 543-4900.
About Fero Industries, Inc.
Fero Industries, Inc. (OTCQB: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for type-2 diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
For investor relations contact:
Paramount Advisors, LLC
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Page: 1 2 3 Related medicine technology :1
. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)2
. Prix Galien USA Honors Innovation in Science and Biotech Industries3
. Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries4
. Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses5
. Roper Industries Schedules Fourth Quarter 2009 Financial Results Conference Call6
. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest7
. Roper Industries Completes the Acquisition of Verathon, Inc.8
. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest and Conversion Rate Adjustment9
. SL Industries Names Louis J. Belardi Chief Financial Officer10
. Newly Re-launched Website Helps PhDs and MDs Capitalize on Growth in Life Science Industries11
. iGPS Announces iGPS bios™, a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries